Phio Pharmaceuticals (NASDAQ:PHIO) Stock: Insider Robert Bitterman Buys 25,000 Shares

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) CEO Robert Bitterman acquired 25,000 shares of Phio Pharmaceuticals stock in a transaction that occurred on Monday, November 9th. The stock was acquired at an average cost of $0.82 per share, with a total value of $20,500.00. Following the purchase, the chief executive officer owned 789,871 shares in the company, valued at $647,694.22. The trade was a 3.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Phio Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:PHIO traded up $0.01 on Tuesday, reaching $0.85. The company had a trading volume of 37,487 shares, compared to its average volume of 1,315,510. The stock has a market capitalization of $9.87 million, a P/E ratio of -0.68 and a beta of 0.93. The stock has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.08. Phio Pharmaceuticals Corp. has a twelve month low of $0.75 and a twelve month high of $1.88.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.36). On average, sell-side analysts predict that Phio Pharmaceuticals Corp. will post -1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on PHIO shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.